Author(s): Richter JA, Rodrguez M, Rioja J, Peuelas I, MartCliment J,
Abstract Share this page
Abstract PURPOSE: The purpose of this study was to evaluate a dual tracer 2-deoxy-2-[F-18]fluoro-D: -glucose (FDG) and (11)C-choline positron emission tomography (PET) protocol in the detection of biochemical prostate cancer relapse. PROCEDURES: Seventy-three patients (median Prostate Specific Antigen (PSA) Test value 2.7 ng/ml (1.1-5.4)) after radical treatment. PET scans were performed by means of a ECAT-Exact HR+ in the first 18 patients and in a PET/computed tomography Biograph II in the remaining 55 patients. RESULTS: The sensitivity of (11)C-choline and FDG was 60.6\% and 31\%. In PSA levels over 1.9 ng/ml, sensitivity increased to 80\% and 40\%, respectively. In the group receiving adjuvant hormone therapy, the diagnostic yields were 71.2\% and 43\%, respectively. While (11)C-choline-PET could not differentiate well and poorly differentiated Gleason score patients, FDG-PET results were almost significant (p = 0.058). CONCLUSIONS: A PSA value higher than 1.9 ng/ml determines a significant increase in the diagnostic yield. Adjuvant hormonotherapy has no influence on the PET results. FDG has a better correlation with the Gleason score than (11)C-choline.
This article was published in Mol Imaging Biol
and referenced in Journal of Nuclear Medicine & Radiation Therapy